Rhabdomyosarcoma: Molecular analysis of Igf2, MyoD1 and Myogenin expression

Neoplasma

Volumn 58, Issue 5, 2011, Pages 415-423

  Krskova, L ^a   Augustinakova, A ^a   Drahokoupilova, E ^a   Sumerauer, D ^a   Mudry, P ^b   Kodet, R ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Igf2, MyoD1, myogenin, loss of heterozygosity; Real time RT PCR; Rhabdomyosarcoma

Indexed keywords

MESSENGER RNA; MYOD1 PROTEIN; MYOGENIN; SOMATOMEDIN B; IGF2 PROTEIN, HUMAN; MYOD PROTEIN; MYOD1 MYOGENIC DIFFERENTIATION PROTEIN; MYOG PROTEIN, HUMAN; ONCOPROTEIN; PAX3 FKHR FUSION PROTEIN, HUMAN; PAX3-FKHR FUSION PROTEIN, HUMAN; PAX7 PROTEIN, HUMAN; TRANSCRIPTION FACTOR PAX7; TUMOR MARKER;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MUSCLE DEVELOPMENT; PRESCHOOL CHILD; PROMOTER REGION; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SCHOOL CHILD; SKELETAL MUSCLE; ADULT; BONE MARROW; EMBRYONAL RHABDOMYOSARCOMA; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ADULT; BONE MARROW; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LOSS OF HETEROZYGOSITY; MALE; MUSCLE, SKELETAL; MYOD PROTEIN; MYOGENIN; ONCOGENE PROTEINS, FUSION; PAX7 TRANSCRIPTION FACTOR; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 80052882482     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_05_415     Document Type: Article

References (39)

1. MCDOWELL HP. Update on childhood rhabdomyosarcoma. Arch Dis Child. 2003; 88 (4): 354-7. doi:10.1136/adc.88.4.354.
2. GATTENLOEHNER S, Dockhorn-Dworniczak B, LEUSCHNER I, VINCENT A, Müller-Hermelink HK, et al. A Comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissue. Journal of Mol Diagnostics 1999; 1: 23-31. doi:10.1016/S1525-1578(10)60605-8.
3. BARR FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001; 20: 5736-46. doi:10.1038/sj.onc.1204599.
4. ANDERSON J, GORDON A, MCMANUS A, SHIPLEY J, Pritchard-Jones K. Disruption of Imprinted Genes at Chromosome Region 11p15.5 in Paediatric Rhabdomyosarcoma. Neoplasia 1999; 1 (4): 340-348. doi:10.1038/sj.neo.7900052.
5. VISSER M, SIJMONS C, BRAS J, ARCECI RJ, GODFRIED M, et al. Allelotype of pediatric rhabdomyosarcoma. Oncogene 1997; 15: 1309-1314 doi:10.1038/sj.onc.1201302.
6. STEENMAN MJ, RAINIER S, DOBRY CJ, GRUNDY P, HORON IL, et al. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms'tumour. Nat Genet. 1994; 7: 433-9.
7. ZHAN S, SHAPIRO DN, HELMAN LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest. 1994; 94: 445-8. doi:10.1172/JCI117344.
8. ZHANG L, KIM M, CHOI MK, GOEMANS B, YEUNG C, et al. Diminished G1 Checkpoint after γ-Irradiation and Altered Cell Cycle Regulation by Insulin-like Growth Factor II Overexpression. J Biol Chem. 1999; 274: 13118-126. doi:10.1074/jbc.274.19.13118.
9. REIK W, MAHER ER.: Imprinting in clusters: lessons from Beckwith-Wiedemann syndrome. Trends Genet. 1997; 13(8): 330-4. doi:10.1016/S0168-9525(97)01200-6.
10. MIYAKI M. Imprinting and colorectal cancer. Nat Med. 1998; 4: 1236-7. doi:10.1038/3214.
11. KHAN J, BITTNER ML, SAAL LH, TEICHMANN U, Azorsa DO, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci U S A. 1999; 96: 13264-9. doi:10.1073/pnas.96.23.13264.
12. STEWART CE, JAMES PL, FANT ME, ROTWEIN P. Overexpression of insulin-like growth factor-II induces accelerated myoblast differentiation. J Cell Physiol. 1996; 169: 23-32. doi:10.1002/(SICI)1097-4652(199610)169:1<23::AID-JCP3>3.0.CO;2-G.
13. STEWART CE, ROTWEIN P. Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts. J Biol Chem. 1996; 271: 11330-8. doi:10.1074/jbc.271.19.11330.
14. PRELLE K, WOBUS AM, KREBS O, BLUM WF, WOLF E. Overexpression of insulin-like growth factor-II in mouse embryonic stem cells promotes myogenic differentiation. Biochem Biophys Res Commun. 2000; 277: 631-8. doi:10.1006/bbrc.2000.3737.
15. WILSON EM, ROTWEIN P. Control of MyoD function during initiation of muscle differentiation by an autocrine signaling pathway activated by insulin-like growth factor-II. J Biol Chem. 2006; 281: 29962-71. doi:10.1074/jbc.M605445200.
16. WEINTRAUB H. The MyoD family and myogenesis: redundancy, networks, and thresholds. Cell. 1993; 75: 1241-4. doi:10.1016/0092-8674(93)90610-3.
17. RUDNICKI MA, SCHNEGELSBERG PN, STEAD RH, BRAUN T, ARNOLD HH, et al. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell. 1993; 75:1351-9. doi:10.1016/0092-8674(93)90621-V.
18. HASTY P, BRADLEY A, MORRIS JH, EDMONDSON DG, VENUTI JM, et al. Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. Nature. 1993; 364(6437):501-6. doi:10.1038/364501a0.
19. OLSON EN, ARNOLD HH, RIGBY PW, WOLD BJ. Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell. 1996; 85:1-4. doi:10.1016/ S0092-8674(00)81073-9.
20. DAVIS RL, WEINTRAUB H, LASSAR AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987; 24; 51: 987-1000.
21. KRSKOVÁ L, MRHALOVÁ M, HILSKÁ I, SUMERAUER D, DRAHOKOUPILOVÁ E, et al. Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma. Virchows Archiv. 2010; 456: 463-472. doi:10.1007/s00428-010-0913-9.
22. BIJWAARD KE, AGUILERA NS, MONCZAK Y, TRUDEL M, TAUBENBERGER JK, et al. Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem. 2001 47: 195-201.
23. DECHIARA TM, EFSTRATIADIS A, ROBERTSON EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature. 1990; 345(6270): 78-80. doi:10.1038/345078a0.
24. ULANER GA, VU TH, LI T, HU JF, YAO XM, et al. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet. 2003; 12: 535-49. doi:10.1093/hmg/ddg034.
25. OGAWA O, ECCLES MR, SZETO J, MCNOE LA, YUN K, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms'tumour. Nature. 1993; 362: 749-51. doi:10.1038/362749a0.
26. CUI H, HORON IL, OHLSSON R, HAMILTON SR, FEINBERG AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med. 1998; 4: 1276-80. doi:10.1038/3260.
27. BRACZKOWSKI R, SCHALLY AV, PLONOWSKI A, VARGA JL, GROOT K, et al. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormonereleasing hormone: effects on insulin-like growth factor II. Cancer. 2002; 95: 1735-45. doi:10.1002/cncr.10865.
28. HAHN H, WOJNOWSKI L, SPECHT K, KAPPLER R, Calzada-Wack J, et al. Patched Target Igf2 is Indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chemistry 2000; 257: 28341-28344. doi:10.1074/jbc.C000352200.
29. SCRABLE H, CAVENEE W, GHAVIMI F, LOVELL M, MORGAN K, et al. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci U S A. 1989; 86: 7480-4. doi:10.1073/pnas.86.19.7480.
30. SCRABLE H, WITTE D, SHIMADA H, SEEMAYER T, SHENG WW, et al. Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer. 1989; 1:23-35. doi:10.1002/gcc.2870010106.
31. MINNITI CP, LUAN D, O'Grady CH, ROSENFELD RG, OH Y, et al. Insulin-like Growth Factor II Overexpression in Myoblasts Induces Phenotypic Changes Typical of the Malignant Phenotype. Cell Growth Diff. 1995; 6; 263-69.
32. WILLIAMSON D, MISSIAGLIA E, DE REYNIES A, PIERRON G, THUILLE B, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncology 2010; 28: 2151-2158. doi:10.1200/JCO.2009.26.3814.
33. CHEN B, DIAS P, JENKINS JJ 3RD, SAVELL VH, PARHAM DM. Methylation alterations of the MyoD1 upstream region are predictive of subclassification of human rhabdomyosarcomas. Am Jf Pathology 1998; 152: 1071-1079
34. DAVICIONI E, FINCKENSTEIN FG, SHAHBAZIAN V, BUCKLEY JD, TRICHE TJ, et al.: Identification of a PAXFKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006; 66:6936-46. doi:10.1158/0008-5472. CAN-05-4578.
35. DIAS P, CHEN B, DILDAY B, PALMER H, HOSOI H, et al. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 2000; 2: 399-408. doi:10.1016/S0002-9440(10)64743-8.
36. KUMAR S, PERLMAN E, HARRIS CA, RAFFELD M, TSOKOS M. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. Mod Pathol 2000; 13: 988-93. doi:10.1038/modpathol.3880179.
37. COFFIN, C M, RULON, J, SMITH, L, BRUGGERS C, WHITE FV. Pathologic features of rhabomyosarcoma before and after treatment: A clinicopathologic and immunohistochemical analysis. Mod Pathol 1997; 10: 1175-87
38. BARR FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997; 19:483-91. doi:10.1097/00043426-199711000-00001.
39. BARR FG. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma. Cancer Res 1999; 59 (7 Suppl): 1711-15.